Song, Nguyen, Shi, Refaat, Pham, Xu, Ren, Skoraczynski, Nguyen, Liu, Klesen, Trépout, Vidallon, Peter, & Wang (2026). Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.. Circulation research.
Song, Nguyen, Shi, Refaat, Pham, Xu, et al. Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.. Circulation research. 2026; PMID: 42148835
Song, Nguyen, Shi, et al. Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.[J]. Circulation research. 2026.
@article{song2026,
author = {Song and Nguyen and Shi and Refaat and Pham and Xu and Ren and Skoraczynski and Nguyen and Liu and Klesen and Trépout and Vidallon and Peter and Wang},
title = {Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.},
journal = {Circulation research},
year = {2026},
note = {PMID: 42148835},
}
TY - JOUR AU - Song AU - Nguyen AU - Shi AU - Refaat AU - Pham AU - Xu AU - Ren AU - Skoraczynski AU - Nguyen AU - Liu AU - Klesen AU - Trépout AU - Vidallon AU - Peter AU - Wang TI - Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis. T2 - Circulation research PY - 2026 AN - PMID:42148835 ER -
Thrombosis is a major contributor to morbidity and mortality in cardiovascular diseases. Although current antiplatelet therapies reduce thrombotic complications, they are associated with systemic bleeding complications. We previously developed a single-chain variable fragment (scFv) that specifically binds and blocks the activated platelet integrin αIIbβ3 (GPIIb/IIIa [glycoprotein IIb/IIIa]), preventing thrombosis without impairing hemostasis. We hypothesized that an mRNA-based therapeutic encoding scFv